-
The AFFIRM study was a randomized comparison of 2 strategies for management of patients with atrial fibrillation. Patients with atrial fibrillation requiring therapy, who also had one or more risk factors for stroke or death, were randomized to either a rate control strategy of cardioversion and treatment with antiarrhythmic drugs or a rate control strategy using atrioventricular (AV) nodal blocking agents to control ventricular response. Results of this study suggest that if an effective method for maintaining sinus rhythm with fewer adverse effects were available, it might improve survival.
-
-
The FDA has approved another rapid-acting insulin to cover mealtime blood sugar spikes.
-
Seizures should be a red flag to consider treatment to modify stroke risk.
-
In this cross-sectional population based study from California, it is apparent that screening is currently applied to older women without consideration of health status.
-
-
The National Cholesterol Education Program (NCEP), a product of a collaboration of the National Heart, Lung, and Blood Institutes, the American College of Cardiology, and the American Heart Association, has updated its clinical practice guideline on cholesterol management.
-
The benefit of ICD therapy, compared to amiodarone therapy in patients with life-threatening arrhythmia, continues to increase over time, and long-term data support the use of an ICD as first line therapy for secondary prevention of sudden cardiac death.
-
Annual, or less frequent, surveillance intervals are effective for aneurysms < 45 mm in diameter.
-
A new portrait of CAM use in the United States. Altern Med Alert 2004;7(9):S1-S2.
